Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, Second Edition

Copyright © 2011 Blackwell Publishing Ltd.

Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, Second Edition

Editor(s): Peter M. Irving, Corey A. Siegel, David S. Rampton, Fergus Shanahan

Published Online: 30 JAN 2012 09:37AM EST

Print ISBN: 9781444334548

Online ISBN: 9781444342574

DOI: 10.1002/9781444342574

About this Book

Product Information

About The Product

The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. 

In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease.  The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.

Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.

This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.

Table of contents

    1. You have free access to this content
      Front Matter (pages i–xv)

  2. Part I: Genes and Phenotype in IBD

    1. Chapter 1

      Which will take us Further in IBD—Study of Coding Variation or Epigenetics? (pages 1–6)

      Miles Parkes

    2. Chapter 2

      IBD in Different Ethnic Groups: Same or Different? (pages 7–11)

      Rupert W. L. Leong, Dorothy K. L. Chow and Christian P. Selinger

  3. Part II: Bugs and IBD—Good, Bad, or Indifferent?

    1. Chapter 3

      How does the Risk ofc Infection Influence Management of IBD around the World? (pages 13–18)

      Kiran K. Peddi and Ian Craig Lawrance

    2. Chapter 4

      Traveling with IBD (pages 19–22)

      Ing Shian Soon and Gilaad Kaplan

    3. Chapter 5

      What to do about Hepatitis B and Hepatitis C in Patients with IBD (pages 23–26)

      Morven Cunningham and Graham R. Foster

    4. Chapter 6

      CMV in IBD—Passenger or Pathogen? (pages 27–29)

      Ahmed Kandiel and Bret Lashner

    5. Chapter 7

      Clostridium Difficile in IBD: Impact, Prevention, and Treatment (pages 30–33)

      Ashwin N. Ananthakrishnan and David G. Binion

    6. Chapter 8

      Prebiotics and Synbiotics: Panacea or Placebo (pages 34–37)

      James O. Lindsay

    7. Chapter 9

      Worms: Light at the End of their Burrow (pages 38–40)

      John Leung and Joel V. Weinstock

    8. Chapter 10

      Do we Really Need to Vaccinate all Patients with IBD? (pages 41–44)

      Gauree Gupta and Gil Y. Melmed

  4. Part III: Investigating IBD

    1. Chapter 11

      Biomarkers in IBD: Myth or Marvel? (pages 45–50)

      Richard B. Gearry and Andrew S. Day

    2. Chapter 12

      Radiation Exposure in IBD: How do we Minimize the Dangers? (pages 51–56)

      Owen J. O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher

    3. Chapter 13

      Surveillance Colonoscopy in UC: What is the Best Way to do it? (pages 57–60)

      Matthew D. Rutter

  5. Part IV: Medical Therapy - 5-ASA

    1. Chapter 14

      New 5-ASAs for Ulcerative Colitis: a Tiny Step or Giant Stride Forward? (pages 61–68)

      L. Campbell Levy

    2. Chapter 15

      Do 5-ASAs Prevent Cancer? (pages 69–72)

      Richard Logan and Venkataraman Subramanian

    3. Chapter 16

      Why do we Still Use 5-ASAs in Crohn's Disease? (pages 73–76)

      Stephen B. Hanauer, Henit Yanai and Emma Calabrese

  6. Part IV: Medical Therapy - Steroids

    1. Chapter 17

      Steroids in Crohn's Disease: Do the Benefits Outweigh the Dangers? (pages 77–82)

      A. Hillary Steinhart

  7. Part IV: Medical Therapy - Immunomodulators

    1. Chapter 18

      Thioguanine Nucleotide Measurement: Nonadherent, Underdosed, Shunter, or Refractory? (pages 83–88)

      Miles P. Sparrow

    2. Chapter 19

      Thiopurines and the Sun: What should be Done? (pages 89–93)

      Conal M. Perrett, Jane M. McGregor and Catherine A. Harwood

    3. Chapter 20

      Do Thiopurines Worsen Risk andc prognosis of Cervical Neoplasia? (pages 94–97)

      Melissa A. Smith, Jeremy D. Sanderson, Anna Foley and Peter R. Gibson

    4. Chapter 21

      Optimizing Use of Methotrexate (pages 98–101)

      Anna Foley and Peter R. Gibson

    5. Chapter 22

      Which Calcineurin Inhibitor and When? (pages 102–105)

      A. Barney Hawthorne

  8. Part IV: Medical Therapy - Biologics

    1. Chapter 23

      Are all Anti-TNF Agents the Same? (pages 107–112)

      Jennifer L. Jones

    2. Chapter 24

      One Drug or Two: Do Patients on Biologics Need Concurrent Immunomodulation? (pages 113–116)

      Glen A. Doherty and Adam S. Cheifetz

    3. Chapter 25

      How do we Identify Patients Needing Early Aggressive Therapy and what Should we Use? (pages 117–119)

      Marc Ferrante and S′everine Vermeire

    4. Chapter 26

      What is the Role of Biologics in UC? (pages 120–123)

      Joanna K. Law and Brian Bressler

    5. Chapter 27

      What can we do with Crohn's Patients who Fail or Lose Response to Anti-TNF Therapy? (pages 124–128)

      David T. Rubin

    6. Chapter 28

      Which Extraintestinal Manifestations of IBD Respond to Biologics? (pages 129–132)

      Tina A. Mehta and Chris S. J. Probert

    7. Chapter 29

      Use and Abuse of Biologics in Pregnancy (pages 133–135)

      Marla C. Dubinsky

    8. Chapter 30

      Is Anti-TNF Therapy Safe to Use in People with a History of Malignancy? (pages 136–139)

      Mark Lust and Simon Travis

    9. Chapter 31

      The Risks of Immunomodulators and Biologics: What should we Tell Patients? (pages 140–143)

      Corey A. Siegel

    10. Chapter 32

      When, How, and in whom should we Stop Biologics? (pages 144–147)

      Edouard Louis, Jacques Belaiche and Catherine Reenaers

  9. Part V: Other Treatments

    1. Chapter 33

      Avoiding Drug Interactions (pages 149–155)

      Tim Elliott and Peter M. Irving

    2. Chapter 34

      Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis? (pages 156–158)

      Emmanouil Sinakos and Keith D. Lindor

    3. Chapter 35

      Stem Cell Transplantation for Crohn's: Will it Fulfill its Promise? (pages 159–163)

      Venkataraman Subramanian and Christopher J. Hawkey

    4. Chapter 36

      Complementary Therapy: Is there a Needle in the Haystack? (pages 164–167)

      Shane M. Devlin

  10. Part VI: Surgical Dilemmas in IBD

    1. Chapter 37

      Optimizing IBD Patients for Surgery and Recovery (pages 169–174)

      Jonathan M. Wilson and Alastair Windsor

    2. Chapter 38

      Is Surgery the Best Initial Treatment for Limited Ileocecal Crohn's Disease? (pages 175–177)

      Tom øresland

    3. Chapter 39

      Laparoscopic or Open Surgery for IBD? (pages 178–181)

      Donna Appleton and Michael Hershman

    4. Chapter 40

      Optimizing Management of Perianal Crohn's Disease (pages 182–185)

      David A. Schwartz and Norman R. Clark

    5. Chapter 41

      Does Anti-TNF Therapy Increase the Risk of Complications of Surgery? (pages 186–191)

      Ming Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein

    6. Chapter 42

      Pouches for Indeterminate Colitis and Crohn's Disease: Act now, Pay Later? (pages 192–195)

      Phillip Fleshner

    7. Chapter 43

      Dealing with Pouchitis (pages 196–199)

      Simon D. McLaughlin and Bo Shen

  11. Part VII: Unsolved Issues in IBD

    1. Chapter 44

      Mucosal Healing in IBD: Does it Matter? (pages 201–206)

      Geert D'Haens

    2. Chapter 45

      Vitamin D in IBD: From Genetics to Bone Health via Cancer and Immunology (pages 207–211)

      Helen M. Pappa and Richard J. Grand

    3. Chapter 46

      Got Milk? Medication Use and Nursing in Women with IBD (pages 212–214)

      Sunanda Kane

    4. Chapter 47

      Does Stress Matter? (pages 215–217)

      Robert G. Maunder

    5. Chapter 48

      IBS is Common in IBD: Fact or Fallacy? (pages 218–221)

      James Goodhand and David S. Rampton

    6. Chapter 49

      So where is all the Cancer? (pages 222–225)

      Judith E. Baars and C. Janneke van der Woude

  12. Part VIII: Nutrition in IBD

    1. Chapter 50

      What should Patients with IBD Eat? (pages 227–232)

      Emile Richman, Keith Leiper and Jonathan M. Rhodes

    2. Chapter 51

      Enteral Nutrition in Crohn's—who for, when, how and which Formula? (pages 233–236)

      Raanan Shamir and Ernest G. Seidman

    3. Chapter 52

      Optimizing Treatment of Iron Deficiency Anemia (pages 237–240)

      Hermann Schulze and Axel Dignass

  13. Part IX: Management Process

    1. Chapter 53

      IBD Standards: Will they Enhance Patient Care? (pages 241–246)

      Michael D. Kappelman

    2. Chapter 54

      Your Treatment will not Work if the Patient does not take it (pages 247–250)

      Rob Horne

    3. Chapter 55

      Inflammatory Bowel Disease: What to Tell Your Emergency Department (ED) Team (pages 251–254)

      Louise Langmead

    4. Chapter 56

      Transitioning from Pediatric to Adult Care (pages 255–257)

      Elizabeth J. Hait and Laurie N. Fishman

    5. Chapter 57

      Medicolegal Pitfalls in Inflammatory Bowel Disease Care (pages 258–260)

      William J. Tremaine

    1. You have free access to this content
      Index (pages 261–268)

SEARCH